Oklahoma Secures $12 Million from Eight Opioid Manufacturers in Multi-State Settlement

OKLAHOMA CITY — Attorney General Gentner Drummond announced Thursday that eight opioid drug manufacturers will pay Oklahoma approximately $12 million as part of a multi-state settlement over allegations that the companies contributed to the national opioid crisis.

The settlement resolves claims against Alvogen, Amneal, Apotex, Hikma, Indivior, Mylan, Sun Pharma, and Zydus — generic pharmaceutical manufacturers accused of fueling the opioid epidemic through their production and distribution of prescription painkillers. The companies were alleged to have downplayed addiction risks and failed to monitor suspicious orders.

Context: Oklahoma's Ongoing Battle

This latest settlement adds to Oklahoma's growing opioid abatement fund, which now exceeds $1 billion when combined with previous agreements reached with major distributors and pharmacy chains. The state has been at the forefront of opioid litigation since 2019, when then-Attorney General Mike Hunter secured a landmark $465 million judgment against Johnson & Johnson.

"These settlements represent accountability," Drummond said in a statement. "For too long, these manufacturers prioritized profits over public health. These funds will help Oklahoma families access the treatment and recovery services they desperately need."

Where the Money Goes

Under Oklahoma's Opioid Abatement framework, settlement funds are distributed through a structured process overseen by the Opioid Abatement Board. The 2026-2027 funding priorities include:

Treatment expansion — Increasing access to medication-assisted treatment (MAT) in rural and underserved areas
Prevention programs — School-based education and community outreach initiatives
Harm reduction — Naloxone distribution and overdose prevention training
Recovery support services — Housing, employment assistance, and peer support programs

The state has already allocated millions in previous settlement rounds to expand treatment capacity, with new MAT programs launched in 17 counties that previously had no opioid treatment providers.

National Settlement Landscape

The Oklahoma settlement is part of a broader wave of manufacturer settlements negotiated by a coalition of state attorneys general. Generic manufacturers — which produce lower-cost versions of brand-name drugs — have faced increasing scrutiny for their role in flooding the market with inexpensive opioid pills.

Unlike the Purdue Pharma/Sackler bankruptcy settlement, which is paying out $7.4 billion nationally over time, these manufacturer settlements provide more immediate cash flow to states for abatement programs.

Impact for Families

For Oklahoma families affected by addiction, the settlement means expanded access to services that can be difficult to find in a largely rural state. Oklahoma ranks among the top states for prescription opioid misuse, with significant disparities between urban and rural access to treatment.

The Opioid Abatement Board accepts grant applications from community organizations, health departments, and treatment providers. Recent awards have funded:

Mobile treatment units serving rural southeastern Oklahoma
Family navigation services to help loved ones find appropriate care
Expansion of the 211 helpline to include substance use resources
Training for first responders in overdose reversal

What's Next

The $12 million will be disbursed according to Oklahoma's existing opioid settlement allocation formula, with portions directed to state-level abatement programs and local government entities. The Opioid Abatement Board will announce the next grant funding round this fall.

For families seeking help, Oklahoma maintains a 24/7 treatment referral helpline at 211 or through the SAMHSA National Helpline at 1-800-662-4357.

If you or someone you love is struggling with opioid addiction, help is available 24/7. Call the SAMHSA National Helpline at 1-800-662-HELP (4357) for free, confidential treatment referral and information.